Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]
Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Cytokinetics (NASDAQ:CYTK) was given a new $83.00 price target on by analysts at Leerink Partners.
Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript [Seeking Alpha]